Talking about what others are afraid to say
Few sentences can destroy billions of dollars of market value faster than this one: “The study did not meet its primary endpoint.” Stocks plummet. Headlines pronounce the trial a failure. …
The Drug Missed Its Endpoint. What Does That Actually Mean? Read More
The pharmaceutical industry is back on another acquisition spree. Nearly every week brings news that a major pharmaceutical company is acquiring a biotech with a promising new therapy or platform. …
Big Pharma Is Buying Innovation Again. Have They Given Up on Their Own R&D? Read More
It seems like every year or two, we get another headline-grabbing number from the pharmaceutical industry about how much it costs to create a new drug. The latest, from the …
Why Deloitte’s “$2.7 Billion to Bring a Drug to Market” Number Is Wrong Read More
Competition for unique, early-stage drugs has become so intense that the average upfront payment for a Phase I asset has risen to approximately $350 million. But don’t be fooled by …
Why $350M Phase I Upfronts Don’t Mean Assets Are Suddenly “Worth More” Read More
Early access to new drugs is often framed as compassionate and patient-centered, but it can backfire. Without solid evidence, patients may be exposed to unknown risks, driven by hype rather …
Rethinking Early Access: Patient Safety First Read More
Given his views on vaccines, pharma companies, and medical science, if Robert F. Kennedy Jr. assumed control of the FDA, it could have profound implications for public health. Kennedy is …
The Danger of An RFK Jr Leading The FDA Read More
The pandemic led to massive increases in research and development among pharmaceutical companies as they raced to discover vaccines and treatments for Covid-19. But those days are over, and many …
The Impact of Weight Loss Drug Market on Cancer Research Read More
The quest for the next blockbuster drug is a high-stakes game in the pharma industry. Two main paths lead to this coveted prize: internal R&D, the detailed but potentially rewarding …
Buying vs. R&D: Is it Cheaper to Acquire Existing Biotechs or Invest in Your Own R&D? Read More